ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » California » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in California

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
KEVIN BORAN M.D.

Cardiovascular Disease

15,913

$1.08M

1251
1109 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 28%

$68
Average prescription price

Avg: $67

BENJAMIN POTKIN M.D.

Cardiovascular Disease

14,966

$890K

1064
934 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 28%

$59
Average prescription price

Avg: $67

CHEUNG LEUNG M. D.

Cardiovascular Disease

14,796

$1.11M

574
502 are 65+

2%
patients receiving schedule two controlled substances

Avg: 0%

14%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 28%

$75
Average prescription price

Avg: $67

HAROUTIOUN MESROBIAN M.D.

Cardiovascular Disease

14,585

$883K

655
588 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

40%
prescriptions for brand name drugs

Avg: 28%

$61
Average prescription price

Avg: $67

SIU WONG M.D.

Cardiovascular Disease

14,345

$1.51M

325
306 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

14%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

59%
prescriptions for brand name drugs

Avg: 28%

$105
Average prescription price

Avg: $67

RAJIV PUNJYA M.D.

Cardiovascular Disease

14,041

$952K

1133
964 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 28%

$68
Average prescription price

Avg: $67

MOHAMED KHAN M.D.

Cardiovascular Disease

13,758

$958K

1295
1043 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

1%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 28%

$70
Average prescription price

Avg: $67

MANUEL AGUILERA M.D.

Cardiovascular Disease

13,650

$985K

473
427 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

6%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

40%
prescriptions for brand name drugs

Avg: 28%

$72
Average prescription price

Avg: $67

EDGAR ALEMAN MD

Cardiovascular Disease

13,340

$866K

763
738 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$65
Average prescription price

Avg: $67

STEVE SEEKOOK PARK M.D.

Cardiovascular Disease

13,244

$795K

1006
964 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

45%
prescriptions for brand name drugs

Avg: 28%

$60
Average prescription price

Avg: $67

IRAJ DARDASHTI MD

Cardiovascular Disease

13,224

$889K

475
458 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

43%
prescriptions for brand name drugs

Avg: 28%

$67
Average prescription price

Avg: $67

MEHRAN MOUSSAVIAN DO

Cardiovascular Disease

12,856

$548K

1105
959 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 28%

$43
Average prescription price

Avg: $67

TRI NGUYEN M.D.

Cardiovascular Disease

12,772

$971K

919
839 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$76
Average prescription price

Avg: $67

SONIA SAWAL M.D.

Cardiovascular Disease

12,256

$508K

463
418 are 65+

8%
patients receiving schedule two controlled substances

Avg: 0%

28%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

14%
prescriptions for brand name drugs

Avg: 28%

$41
Average prescription price

Avg: $67

KHALDOUN SROUJIEH

Cardiovascular Disease

12,234

$656K

494
458 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 28%

$54
Average prescription price

Avg: $67

JOEL JUAREZ-URIBE M.D.

Cardiovascular Disease

12,214

$402K

383
354 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

11%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 28%

$33
Average prescription price

Avg: $67

ROHIT SUNDRANI M.D.

Cardiovascular Disease

12,038

$829K

918
783 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$69
Average prescription price

Avg: $67

ROLLINGTON FERGUSON MD

Cardiovascular Disease

12,011

$907K

546
325 are 65+

3%
patients receiving schedule two controlled substances

Avg: 0%

26%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

35%
prescriptions for brand name drugs

Avg: 28%

$75
Average prescription price

Avg: $67

HUGO RIFFEL DALINGER MD

Cardiovascular Disease

11,987

$910K

775
740 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

42%
prescriptions for brand name drugs

Avg: 28%

$76
Average prescription price

Avg: $67

STANLEY LAU M.D.

Cardiovascular Disease

11,873

$515K

1222
1157 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 28%

$43
Average prescription price

Avg: $67

MICHAEL GEN M.D.

Cardiovascular Disease

11,862

$847K

887
764 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$71
Average prescription price

Avg: $67

JEROME ROBINSON MD

Cardiovascular Disease

11,728

$811K

362
301 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 28%

$69
Average prescription price

Avg: $67

GOPAL GOVINDARAJAN M.D. F.A.C.C.

Cardiovascular Disease

11,538

$700K

344
296 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

19%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 28%

$61
Average prescription price

Avg: $67

JAIRO MARIN M.D.

Cardiovascular Disease

11,503

$406K

687
633 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 28%

$35
Average prescription price

Avg: $67

RAJESH SURI MD

Cardiovascular Disease

11,440

$796K

419
342 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

22%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$70
Average prescription price

Avg: $67

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank